



Express Mail No.: EV 452 776 714 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Donald J. KYLE et al.

Confirmation No.: 8122

Application No.: 10/625,708

Group Art Unit: 1624

Filed: July 24, 2003

Examiner: Kahsay Habte, Ph.D.

Title: THERAPEUTIC AGENTS USEFUL

Attorney Docket No.: 6750-174-999

FOR TREATING PAIN

(CAM No.: 305158-999172)

CONTINUATION OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56 and 1.97

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §§ 1.56 and 1.97 to inform the Patent and Trademark Office ("Office") of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or may be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to reference **B16**, which is listed on the accompanying Form PTO-1449 entitled "Information Disclosure Statement By Applicant." This Continuation Of Supplemental Information Disclosure Statement supplements the Supplemental Information Disclosure Statement filed on February 16, 2006 and the Information Disclosure Statement filed on October 5, 2005. Reference B16 was inadvertently omitted from the Supplemental Information Disclosure Statement filed on February 16, 2006.

A legible copy of reference **B16** is submitted herewith.

No admission is made that the information cited in this Continuation Of Supplemental Information Disclosure Statement is, or is considered to be, material to patentability and no representation is made that a search has been made. 37 C.F.R. §§ 1.97(g) and (h).

Applicants request that the Examiner review the reference identified on the attached Form PTO-1449, and that it be made of record in the file history of the above-identified application.

This Continuation Of Supplemental Information Disclosure Statement is filed under 37 C.F.R. § 1.97(c) after the period specified in 37 C.F.R. § 1.97(b), but before the mailing date of any of a final action under 37 C.F.R. § 1.113, a notice of allowance under 37 C.F.R. § 1.311 or an action that otherwise closes prosecution in the application. However, the Applicants believe that no fee is due as the \$180.00 fee set forth in 37 C.F.R. § 1.17(p) in accordance with 37 C.F.R. § 1.97(c) was paid with the Supplemental Information Disclosure Statement filed on February 16, 2006. Please charge any required fee to Jones Day Deposit Account No. 50-3013.

Date: February 17, 2006

Respectfully submitted,

Samuel B. Abrams

(Reg. No. 30,605)

JONES DAY

222 East 41st Street

New York, New York 10017

(212) 326-3939

Enclosures



Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)

ATTY	DOCKET	NO.
6750-1	74-999	

APPLICATION NO.

(CAM No. 305158-999172)

10/625,708

APPLICANT:

Donald J. KYLE et al.

FILING DATE:

ART UNIT:

CONF. NO.:

July 24, 2003

1624

8122

	U.S. PATENT DOCUMENTS				
EXAMINER'S INITIALS*	Cite No.	DOCUMENT NUMBER	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A28				

FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS*	Cite No.	Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLA	TION
						YES	NO
	B16	WO 00/42852	07/27/2000	Smithkline Beecham Corp.			
	B17						

NON PATENT LITERATURE DOCUMENTS				
EXAMINER'S INITIALS*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.,), date, page(s)s, volume, publisher, city and/or country where published., etc.		
	C41			

DATE CONSIDERED